HLB bioStep Statistics

Total Valuation

HLB bioStep has a market cap or net worth of KRW 145.83 billion. The enterprise value is 138.60 billion.

Market Cap	145.83B
Enterprise Value	138.60B

Important Dates

The last earnings date was Thursday, March 20, 2025.

Earnings Date	Mar 20, 2025
Ex-Dividend Date	n/a

Share Statistics

HLB bioStep has 84.20 million shares outstanding. The number of shares has increased by 4.42% in one year.

Current Share Class	n/a
Shares Outstanding	84.20M
Shares Change (YoY)	+4.42%
Shares Change (QoQ)	-4.76%
Owned by Insiders (%)	4.98%
Owned by Institutions (%)	4.62%
Float	65.74M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.55
PB Ratio	1.30
P/TBV Ratio	1.43
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-16.18
EV / Sales	2.38
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.73

Financial Position

The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.30.

Current Ratio	1.35
Quick Ratio	1.20
Debt / Equity	0.30
Debt / EBITDA	n/a
Debt / FCF	-1.68
Interest Coverage	-15.19

Financial Efficiency

Return on equity (ROE) is -8.80% and return on invested capital (ROIC) is -5.17%.

Return on Equity (ROE)	-8.80%
Return on Assets (ROA)	-4.80%
Return on Invested Capital (ROIC)	-5.17%
Return on Capital Employed (ROCE)	-10.69%
Revenue Per Employee	387.79M
Profits Per Employee	-57.10M
Employee Count	150
Asset Turnover	0.34
Inventory Turnover	11.33

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -55.14% in the last 52 weeks. The beta is 0.43, so HLB bioStep's price volatility has been lower than the market average.

Beta (5Y)	0.43
52-Week Price Change	-55.14%
50-Day Moving Average	2,238.86
200-Day Moving Average	2,324.41
Relative Strength Index (RSI)	32.51
Average Volume (20 Days)	615,469

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HLB bioStep had revenue of KRW 58.17 billion and -8.56 billion in losses. Loss per share was -100.00.

Revenue	58.17B
Gross Profit	40.83B
Operating Income	-13.05B
Pretax Income	-11.53B
Net Income	-8.56B
EBITDA	-8.34B
EBIT	-13.05B
Loss Per Share	-100.00

Full Income Statement

Balance Sheet

The company has 46.86 billion in cash and 34.70 billion in debt, giving a net cash position of 12.16 billion or 144.48 per share.

Cash & Cash Equivalents	46.86B
Total Debt	34.70B
Net Cash	12.16B
Net Cash Per Share	144.48
Equity (Book Value)	116.81B
Book Value Per Share	1,328.74
Working Capital	16.19B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -11.67 billion and capital expenditures -8.92 billion, giving a free cash flow of -20.59 billion.

Operating Cash Flow	-11.67B
Capital Expenditures	-8.92B
Free Cash Flow	-20.59B
FCF Per Share	-244.60

Full Cash Flow Statement

Margins

Gross margin is 70.19%, with operating and profit margins of -22.43% and -14.72%.

Gross Margin	70.19%
Operating Margin	-22.43%
Pretax Margin	-19.82%
Profit Margin	-14.72%
EBITDA Margin	-14.35%
EBIT Margin	-22.43%
FCF Margin	n/a

Dividends & Yields

HLB bioStep does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.42%
Shareholder Yield	-4.42%
Earnings Yield	-5.87%
FCF Yield	-14.12%

Dividend Details

Stock Splits

The last stock split was on May 31, 2022. It was a forward split with a ratio of 9.

Last Split Date	May 31, 2022
Split Type	Forward
Split Ratio	9

Scores

HLB bioStep has an Altman Z-Score of 3.16.

Altman Z-Score	3.16
Piotroski F-Score	n/a